Acute Radiation Drug Treatment is Studied
A U.S. company says it’s started initial human safety testing of a drug designed to treat exposure to radiation from nuclear weapons or a nuclear accident.
Cleveland BioLabs Inc. said it dosed its first healthy volunteer this month in the human safety study required by the U.S. Food and Drug Administration for the drug Protectan CBLB502.
The safety trial involves single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will be assessed for adverse side effects during a two-week time period and blood samples will be obtained to assess the effects of the drug on various biomarkers.
Officials said the study is expected to take about six months to complete and will be followed by a second, larger safety study in healthy human volunteers.
Cleveland BioLabs received funding contracts totaling $22.2 million from federal agencies for development of the radiation countermeasure.
The company has strategic partnerships with the Armed Forces Radiobiology Research Institute, the Cleveland Clinic, Roswell Park Cancer Institute and the ChemBridge Corp.